Yuensun

Beijing Yuensun Biological Technology is a clinical-stage biotechnology company based in China, specializing in the development of innovative cell therapies for cancer treatment. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) technologies, targeting both hematological malignancies and challenging solid tumors. Yuensun's pipeline includes several candidates currently in clinical trials, aiming to address unmet medical needs in oncology through precision immunotherapy. Their research emphasizes improving the persistence and efficacy of engineered T-cells within the immunosuppressive tumor microenvironment. The company operates a state-of-the-art R&D facility in Beijing and collaborates with leading clinical institutions to advance its therapeutic candidates.